Galecto Scraps Lung Disease Treatment After Trial Failure

Galecto will stop developing its therapy for a disease that causes lung scarring after it failed to meet the main goal of a midstage study, the drug developer said on Tuesday.

Related Keywords

Bengaluru ,Karnataka ,India ,Sriraj Kalluvila ,Arun Koyyur ,Sriparna Roy ,Reuters ,Idiopathic Pulmonary Fibrosis ,Epf ,Diopathic Pulmonary Fibrosis Ipf ,Pf Pulmonary Fibrosis ,Lung ,Lung Fibrosis ,Pulmonary Fibrosis ,Liver Disease ,Hepatic Impairment ,Liver ,Cirrhosis ,